Share count
2.1Bpeak FY2025
← All companies ← RACE Manual RCI → ← QURE Pharmaceuticals RARE →
RADX, Radiopharm Theranostics Limited
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
The business
What it sells, where the money comes from, the kind of company it is.
Revenue · FY2025
$4M
+1114.3% YoY
Vital signs · TTM
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn.
- What moves the needle
- Operating margin has run around −11796% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Capital spending runs about 15% of sales, below what it charges for depreciation, so the return earned on what it sinks into that plant weighs as much as the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −219%, above 15% in 0 of 3 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2023–2025
realized figures from each filing · older years to the left| 2023’23 | 2024’24 | 2025’25 | TTMTTMJun 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| $292K | $299K | $4M | $4M | RevenueRevenue |
| — | — | 1% | 1% | Gross marginGross mgn |
| ($34M) | ($47M) | ($38M) | ($38M) | Operating incomeOp. inc. |
| n/m | n/m | n/m | n/m | Operating marginOp. mgn |
| ($35M) | ($48M) | ($38M) | ($38M) | Net incomeNet inc. |
| Cash flow & returns | ||||
| ($23M) | ($23M) | ($37M) | ($37M) | Operating cash flowOp. cash |
| $3M | $3M | $3M | $3M | DepreciationDeprec. |
| $8M | $22M | ($899K) | ($899K) | Working capital & otherWC & other |
| $45K | — | — | $45K | CapexCapex |
| 15.5% | — | — | 1.2% | Capex / revenueCapex/rev |
| ($23M) | — | — | ($37M) | Owner earningsOwner earn. |
| n/m | — | — | n/m | Owner earnings marginOE mgn |
| ($23M) | — | — | ($37M) | Free cash flowFCF |
| n/m | — | — | n/m | Free cash flow marginFCF mgn |
| -80% | -425% | -219% | -219% | ROICROIC |
| -76% | -175% | -89% | -89% | Return on equityROE |
| −76% | −175% | −89% | −89% | Retained to equityRetained/eq |
| Balance sheet | ||||
| $12M | $19M | $29M | $29M | Cash & investmentsCash+inv |
| $4M | $987K | $10M | $10M | ReceivablesReceiv. |
| $5M | $11M | $9M | $9M | Accounts payablePayables |
| ($655K) | ($10M) | $1M | $1M | Operating working capitalOper. WC |
| — | $23M | $40M | $40M | Current assetsCur. assets |
| — | $18M | $15M | $15M | Current liabilitiesCur. liab. |
| — | 1.3× | 2.7× | 2.7× | Current ratioCurr. ratio |
| — | $72M | $86M | $86M | Total assetsAssets |
| ($12M) | ($19M) | ($29M) | ($29M) | Net debt / (cash)Net debt |
| -400.6× | -73.4× | -584.6× | -584.6× | Interest coverageInt. cov. |
| $46M | $27M | $43M | $43M | Shareholders’ equityEquity |
| Per share | ||||
| 306M | 386M | 2.08B | 2.08B | Shares out (diluted)Shares |
| $0.00 | $0.00 | $0.00 | $0.00 | Revenue / shareRev/sh |
| $-0.11 | $-0.12 | $-0.02 | $-0.02 | EPS (diluted)EPS |
| $-0.08 | — | — | $-0.02 | Owner earnings / shareOE/sh |
| $-0.08 | — | — | $-0.02 | Free cash flow / shareFCF/sh |
| $0.00 | — | — | $0.00 | Cap. spending / shareCapex/sh |
| $0.15 | $0.07 | $0.02 | $0.02 | Book value / shareBVPS |
The diluted share count moved ×5.38 into 2025 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The record, charted
FY2023–2025Each measure over its full record; the current point and the worst year marked.
ROIC
−219%low FY2024
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2023 the business turned a $35M loss into ($23M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2023 | |
|---|---|
| Reported net income | ($35M) |
| Depreciation & amortizationnon-cash charge added back | +$3M |
| Working capital & othertiming of cash in and out, other non-cash items | +$8M |
| Cash from operations | ($23M) |
| Capital expenditurecash put back in to keep running and to grow | −$45K |
| Owner earnings | ($23M) |
| Owner-earnings marginowner earnings ÷ revenue | -7952% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
FY2025 20-F · source on SEC EDGAR →
Will it survive?
- Can it pay its interest? -584.6×Does not cover its interestOperating income ($38M) ÷ interest expense $65K
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net cash, debt-freeCash $29M − debt $0
What this means
Cash and short-term investments exceed every dollar of debt by $29M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Not enough dataIndustry peers: median -54%
What this means
The filing data didn't include the inputs for this check.
- Owner-earnings margin -1010%Consumes cashOwner earnings ($37M) = operating cash ($37M) − maintenance capex $45KIndustry peers: median -1308%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -1010% of revenue this year.
- Are earnings backed by cash? ($37M)Loss, and burning cashNet income ($38M) · cash from operations ($37M)
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.02×HarvestingCapex $45K ÷ depreciation $3M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 1 of 2 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $4M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 2.67×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.02/share (latest year $-0.02), the averaged base the calculator's gate runs on, and book value is $0.02/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Jun 30, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
Current assets$40M
- Cash & short-term investments$29M
- Receivables$10M
- Other current assets$337K
Current liabilities$15M
- Accounts payable$9M
- Other current liabilities$6M
Current ratio2.67×all current assets ÷ what's due · Graham looked for 2×
Quick ratio—inventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio1.95×strictest: cash alone against what's due
Working capital$25Mthe cushion left after near-term bills
Cash runway0.8 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Deeper floors
Tangible book value($4M)equity stripped of goodwill & intangibles
Net current asset value($4M)Graham's net-net: current assets less all liabilities
From the company's latest filing.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| ACRSAclaris Therapeutics Inc. | $8M | 28% | -975.9% | -73% | -603% |
| OVIDOvid Therapeutics Inc. | $7M | — | -2170.9% | -64% | -2143% |
| CPHIChina Pharma Holdings Inc. | $4M | 9% | -65.3% | -29% | -2% |
| ATAIAtaiBeckley Inc. | $4M | — | -15751.1% | -356% | -2533% |
| RADXRadiopharm Theranostics Limited | $4M | 1% | -11796.1% | -219% | -1010% |
| UPBUpstream Bio Inc. | $3M | — | -3281.2% | -53% | -2500% |
| DNTHDianthus Therapeutics Inc. | $2M | — | -1704.7% | -54% | -1308% |
| ORMPOramed Pharmaceuticals Inc. | $2M | 1% | -754.4% | -29% | -479% |
| Group median | — | 5% | -1937.8% | -59% | -1159% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the home-market price, not the US ADR quote. Radiopharm Theranostics Limited reports in USD, and every figure here (owner earnings, book value, the share count) is on that ordinary-share basis. Enter the price on the same basis: the local-exchange quote per ordinary share. A US ADR price in dollars bundles the ADR-to-ordinary ratio, so it will not reconcile with these figures and would throw the multiple off.
Radiopharm Theranostics Limited is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.
$
The assumptions
Enter a price to run it.
Owner earnings it must reach—
Margin the price demands—
Owner-earnings margin today−1010%
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.
Cite: Owner Scorecard, "Radiopharm Theranostics Limited (RADX), the owner's record," https://ownerscorecard.com/c/RADX, data as of 2026-07-09.
Manual order: ← RACE its page in the Manual RCI →
Industry order: ← QURE the Pharmaceuticals chapter RARE →